QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases
August 28 2024 - 4:05PM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the expansion of its Master Collaboration Agreement with
AstraZeneca to develop and commercialize companion diagnostics
(CDx) for AstraZeneca’s future therapies being developed to address
chronic diseases.
Under the agreement, QIAGEN will develop and
validate a genotyping assay using QIAGEN’s syndromic testing
platform QIAstat-Dx. The test will enable specialty care providers
to potentially perform genotyping whilst patients are undergoing
routine clinical examination, thus enabling fast decision making
for potential suitability for AstraZeneca’s genomically targeted
medicines.
“We are pleased to expand our partnership with
AstraZeneca into new disease areas using our QIAstat‑Dx system and
to develop together the first companion diagnostic for chronic
diseases based on this platform”, said Fernando Beils, Senior Vice
President, Head of the Molecular Diagnostics Business Area at
QIAGEN. “The development of the QIAstat-Dx genotyping assay with
AstraZeneca showcases QIAGEN’s expertise in companion diagnostic
development and commercialization, utilizing the most suitable
molecular testing platform to meet the unique clinical and
commercial needs of patient testing.”
The QIAstat-Dx system, designed for laboratory
use, employs cost-efficient, single-use cartridges with built-in
sample processing and on-board reagents. Utilizing multiplex
real-time PCR, it detects and differentiates between multiple
biomarkers, with results in about an hour. QIAstat-Dx also provides
easy‑to‑view cycle threshold (Ct) values and amplification curves,
offering additional insights not available with end-point PCR or
other techniques. At the end of 2023, over 4,000 cumulative
instrument placements had been made.
QIAGEN is a pioneer in precision medicine and
the leader in collaborating with pharmaceutical and biotechnology
companies to develop companion diagnostics. These can detect
genetic abnormalities to provide insights that guide clinical
decision-making about treatments. From polymerase chain reaction
(PCR) and digital PCR (dPCR) to next-generation sequencing (NGS),
QIAGEN offers an unmatched breadth of technologies, which means it
can tailor products to partners’ needs.
QIAGEN has master collaboration agreements to
develop and commercialize companion diagnostics with more than 30
global companies – a deep pipeline that will advance precision
medicine, which tailors a patient’s treatment to the genetic
profile identified by companion diagnostics testing. Furthermore,
QIAGEN has a series of collaborations with Neuron23 and Helix to
develop companion diagnostics in disease areas outside
oncology.
About QIAGENQIAGEN N.V., a
Netherlands-based holding company, is the leading global provider
of Sample to Insight solutions that enable customers to gain
valuable molecular insights from samples containing the building
blocks of life. Our sample technologies isolate and process DNA,
RNA and proteins from blood, tissue and other materials. Assay
technologies make these biomolecules visible and ready for
analysis. Bioinformatics software and knowledge bases interpret
data to report relevant, actionable insights. Automation solutions
tie these together in seamless and cost-effective workflows. QIAGEN
provides solutions to more than 500,000 customers around the world
in Molecular Diagnostics (human healthcare) and Life Sciences
(academia, pharma R&D and industrial applications, primarily
forensics). As of June 30, 2024, QIAGEN employed approximately
5,900 people in over 35 locations worldwide. Further information
can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, timing for launch
and development, marketing and/or regulatory approvals, financial
and operational outlook, growth and expansion, collaborations,
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, and its
impact on the demand for our products and other aspects of our
business, or other force majeure events; as well as the possibility
that expected benefits related to recent or pending acquisitions
may not materialize as expected; and the other factors discussed
under the heading “Risk Factors” contained in Item 3 of our most
recent Annual Report on Form 20-F. For further information, please
refer to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange
Commission.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Domenica Martorana
QIAGEN N.V.
+49 2103 29 11244
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Lisa Specht
QIAGEN N.V.
+49 2103 29 14181
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Oct 2023 to Oct 2024